"discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis"
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00036
- Awardee
-
Inimmune Corp UEI EF8AMXMGG8W5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $631,425
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Pre-Solicitation · PHS20181 · Posted Jun 29, 2017
- Contract value 100% obligated
- $631,425.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Missoula, MT 59802, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$2,892 | |
| Exercise an Option | $41,693 | |
| Original award | $592,624 |
About this award
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Inimmune Corp, a small business biotechnology company, for the "Discovery of New Small Molecule TLR4 Agonists for the Treatment of Allergic Rhinitis". The $631,425.00 Firm Fixed Price contract has a period of performance from July 31, 2018 to July 31, 2020. Inimmune Corp, which has previously supported immunogenicity studies and clinical trials through federal contract awards, will conduct research and development under this contract to discover new vaccine adjuvants and formulations targeting Toll-Like Receptor 4 for the treatment of allergic rhinitis.
Quick answers
Who was awarded contract 75N93018C00036?
75N93018C00036 was awarded to Inimmune Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 31, 2018.
How much is contract 75N93018C00036 worth?
The government has obligated $631,425 on 75N93018C00036.
Was contract 75N93018C00036 competed?
The extent of competition for 75N93018C00036 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award